Quantum Biopharma (QNTM) Gains from Investment Securities (2020 - 2026)
Quantum Biopharma (QNTM) posted Gains from Investment Securities of -$4311.0 for Q1 2026, up 99.96% sequentially from -$12.1 million in Q4 2025, and up 93.69% YoY from -$2225.8 in Q1 2025.
Quantum Biopharma (QNTM) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 8 years of Gains from Investment Securities data on file, last reported at -$4311.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 93.69% year-over-year to -$4311.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$111212.0 (down 147.16% YoY) and the FY2025 annual result came in at -$175194.0, changed N/A from the prior year.
- Gains from Investment Securities climbed to -$4311.0 in Q1 2026 per QNTM's latest filing, from -$12.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $10.7 million in Q2 2025, with the low at -$12.1 million in Q4 2025.
- Average Gains from Investment Securities over 5 years is $3218.9, with a median of $74.0 recorded in 2024.
- The widest YoY moves for Gains from Investment Securities: up 1690813.51% in 2025, down 38760.91% in 2025.
- Quantum Biopharma's Gains from Investment Securities stood at -$142696.0 in 2022, then soared by 179.34% to $113211.0 in 2023, then plunged by 72.39% to $31263.0 in 2024, then tumbled by 38760.91% to -$12.1 million in 2025, then soared by 99.96% to -$4311.0 in 2026.
- Business Quant data shows QNTM's Gains from Investment Securities at -$4311.0 in Q1 2026, -$12.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - |
| 10 | Quantum Biopharma | 15.08 Mn | 8.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,311.00 |
| Mar 31, 2026 | -4,311.00 |
| Dec 31, 2025 | -12.09 Mn |
| Dec 31, 2025 | -12.09 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 10.73 Mn |
| Jun 30, 2025 | 10.73 Mn |
| Mar 31, 2025 | -68,293.00 |
| Mar 31, 2025 | -68,293.00 |
| Dec 31, 2024 | 31,263.00 |
| Dec 31, 2024 | 31,263.00 |
| Sep 30, 2024 | 74.00 |
| Sep 30, 2024 | 74.00 |
| Jun 30, 2024 | -8,040.00 |
| Jun 30, 2024 | -8,040.00 |
| Mar 31, 2024 | -23,297.00 |
| Mar 31, 2024 | -23,297.00 |
| Dec 31, 2023 | 113,211.00 |
| Dec 31, 2023 | 113,211.00 |